Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL.

Antimicrob Agents Chemother. 2008 Sep;52(9):3047-51. doi: 10.1128/AAC.00103-08. Epub 2008 Jul 7.

2.

Stability of colistimethate sodium in aqueous solution.

Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J.

Antimicrob Agents Chemother. 2012 Dec;56(12):6432-3. doi: 10.1128/AAC.01079-12. Epub 2012 Oct 15.

3.

Stability of colistimethate sodium in a disposable elastomeric infusion device.

Abdulla A, van Leeuwen RW, de Vries Schultink AH, Koch BC.

Int J Pharm. 2015;486(1-2):367-9. doi: 10.1016/j.ijpharm.2015.04.008. Epub 2015 Apr 8.

PMID:
25863116
4.

Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K.

Antimicrob Agents Chemother. 2003 Apr;47(4):1364-70.

5.

Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin.

Wollstadt A, Krämer I, Kamin W.

Pharmazie. 2013 Sep;68(9):744-8.

PMID:
24147342
6.

Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation.

Wallace SJ, Li J, Nation RL, Prankerd RJ, Boyd BJ.

J Pharm Sci. 2012 Sep;101(9):3347-59. doi: 10.1002/jps.23203. Epub 2012 May 23.

7.

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H.

Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6. doi: 10.1128/AAC.01361-08. Epub 2009 May 11.

8.

Stability of doripenem in vitro in representative infusion solutions and infusion bags.

Psathas PA, Kuzmission A, Ikeda K, Yasuo S.

Clin Ther. 2008 Nov;30(11):2075-87. doi: 10.1016/j.clinthera.2008.11.013.

PMID:
19108795
9.

Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

Bergen PJ, Li J, Rayner CR, Nation RL.

Antimicrob Agents Chemother. 2006 Jun;50(6):1953-8.

10.

Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K.

J Antimicrob Chemother. 2004 May;53(5):837-40. Epub 2004 Mar 24.

PMID:
15044428
11.
12.

Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.

Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, Kostakou E, Baziaka F, Paskalis C, Koutsoukou A, Giamarellou H.

Antimicrob Agents Chemother. 2015 Dec;59(12):7240-8. doi: 10.1128/AAC.00554-15. Epub 2015 Sep 14.

13.

Self-assembly behavior of colistin and its prodrug colistin methanesulfonate: implications for solution stability and solubilization.

Wallace SJ, Li J, Nation RL, Prankerd RJ, Velkov T, Boyd BJ.

J Phys Chem B. 2010 Apr 15;114(14):4836-40. doi: 10.1021/jp100458x.

14.

Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.

Imberti R, Cusato M, Accetta G, Marinò V, Procaccio F, Del Gaudio A, Iotti GA, Regazzi M.

Antimicrob Agents Chemother. 2012 Aug;56(8):4416-21. doi: 10.1128/AAC.00231-12. Epub 2012 Jun 11.

15.

Stability and preservation of a new formulation of epoprostenol sodium for treatment of pulmonary arterial hypertension.

Lambert O, Bandilla D.

Drug Des Devel Ther. 2012;6:235-44. doi: 10.2147/DDDT.S31628. Epub 2012 Sep 17.

16.

High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study.

Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N.

Clin Infect Dis. 2012 Jun;54(12):1720-6. doi: 10.1093/cid/cis286. Epub 2012 Mar 15.

17.

Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

He H, Li JC, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J.

J Antimicrob Chemother. 2013 Oct;68(10):2311-7. doi: 10.1093/jac/dkt207. Epub 2013 Jun 7.

18.

Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage.

Dudhani RV, Nation RL, Li J.

J Antimicrob Chemother. 2010 Jul;65(7):1412-5. doi: 10.1093/jac/dkq134. Epub 2010 Apr 22.

19.

[Shedding light on the use of colistin: still gaps to be filled].

Luque S, Grau S, Berenguer N, Horcajada JP, Sorlí L, Montero MM, Salas E.

Enferm Infecc Microbiol Clin. 2011 Apr;29(4):287-96. doi: 10.1016/j.eimc.2011.02.003. Review. Spanish.

PMID:
21440335
20.

New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.

Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W.

Antimicrob Agents Chemother. 2014 Dec;58(12):7324-30. doi: 10.1128/AAC.03508-14. Epub 2014 Sep 29.

Supplemental Content

Support Center